Bloomberg -- Novartis AG’s fourth-quarter profit fell 6 percent as sales of influenza vaccine declined following the end of the flu pandemic and the company wrote down the value of a cancer drug. The stock fell the most in almost seven months.
Bloomberg -- Novartis AG’s fourth-quarter profit fell 6 percent as sales of influenza vaccine declined following the end of the flu pandemic and the company wrote down the value of a cancer drug. The stock fell the most in almost seven months.